The role for microRNAs in drug toxicity and in safety assessment

Bibliography

• Guengerich FP. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet 2011;26:3-14
   PubMed Web of Science ®Google Scholar
• Borroni RG. Pharmacogenetic markers of severe cutaneous adverse drug reactions. G Ital Dermatol Venereol 2014;149:219-26
   PubMed Web of Science ®Google Scholar
• Kongkaew C, Hann M, Mandal J, et al. Risk factors for hospital admissions associated with adverse drug events. Pharmacotherapy 2013;33:827-37
   PubMed Web of Science ®Google Scholar
• Phillips AL, Nigro O, Macolino KA, et al. Hospital admissions caused by adverse drug events: an Australian prospective study. Aust Health Rev 2014;38:51-7
   PubMed Web of Science ®Google Scholar
• Miguel A, Azevedo LF, Araújo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2012;21:1139-54
   PubMed Web of Science ®Google Scholar
• Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20
   PubMed Web of Science ®Google Scholar
• Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, et al. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf 2011;20:772-7
   PubMed Web of Science ®Google Scholar
• FDA Adverse Event Reporting System (FAERS). Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070434.htm
   Google Scholar
• ICH guidelines. Available from: http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html
   Google Scholar
• Murchison EP, Hannon GJ. miRNAs on the move: miRNA biogenesis and the RNAi machinery. Curr Opin Cell Biol 2004;16:223-9
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33
   PubMed Web of Science ®Google Scholar
• Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847-65
   PubMed Web of Science ®Google Scholar
• Wilczynska A, Bushell M. The complexity of miRNA-mediated repression. Cell Death Differ 2015;22(1):22-33
   PubMed Web of Science ®Google Scholar
• Avraham R, Yarden Y. Regulation of signalling by microRNAs. Biochem Soc Trans 2012;40:26-30
   PubMed Web of Science ®Google Scholar
• Lee I, Ajay SS, Yook JI, et al. New class of microRNA targets containing simultaneous 5′-UTR and 3′-UTR interaction sites. Genome Res 2009;19:1175-83
   PubMed Web of Science ®Google Scholar
• Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010;10:389-402
   PubMed Web of Science ®Google Scholar
• Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res 2007;61:24R-9R
   PubMed Web of Science ®Google Scholar
• Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 2009;14:162-7
   PubMed Web of Science ®Google Scholar
• Ferri N, Siegl P, Corsini A, et al. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther 2013;138:470-84
   PubMed Web of Science ®Google Scholar
• Horie T, Ono K, Nishi H, et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 2010;87:656-64
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Kondo C, Morikawa Y, et al. Plasma miR-208 as a useful biomarker for drug-induced cardiotoxicity in rats. J Appl Toxicol 2015;35:173-80
   PubMed Web of Science ®Google Scholar
• Vacchi-Suzzi C, Bauer Y, Berridge BR, et al. Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PLoS One 2012;7:e40395
   PubMed Web of Science ®Google Scholar
• Fu J, Peng C, Wang W, et al. Let-7g is involved in doxorubicin induced myocardial injury. Environ Toxicol Pharmacol 2012;33:312-17
   PubMed Web of Science ®Google Scholar
• Desai VG, C Kwekel JC, Vijay V, et al. Early biomarkers of doxorubicin-induced heart injury in a mouse model. Toxicol Appl Pharmacol 2014;281:221-9
   PubMed Web of Science ®Google Scholar
• Qi W-X, Fu S, Zhang Q, Guo X-M. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups. Clin Drug Investig 2014;34:681-90
   PubMed Web of Science ®Google Scholar
• Zhao Z, He J, Zhang J, et al. Dysregulated miR1254 and miR579 for cardiotoxicity in patients treated with bevacizumab in colorectal cancer. Tumour Biol 2014;35:5227-35
   PubMed Web of Science ®Google Scholar
• Ji X, Takahashi R, Hiura Y, et al. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 2009;55:1944-9
   PubMed Web of Science ®Google Scholar
• Liu L, Aguirre SA, Evering WEN, et al. miR-208a as a biomarker of isoproterenol-induced cardiac injury in Sod2+/- and C57BL/6J wild-type mice. Toxicol Pathol 2014;42:1117-29
   PubMed Web of Science ®Google Scholar
• Amacher DE, Schomaker SJ, Aubrecht J. Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics. Mol Diagn Ther 2013;17:343-54
   PubMed Web of Science ®Google Scholar
• Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury – past, present, and future. Clin Pharmacol Ther 2012;92:332-9
   PubMed Web of Science ®Google Scholar
• Yokoi T, Nakajima M. microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 2013;53:377-400
   PubMed Web of Science ®Google Scholar
• Marrone AK, Beland FA, Pogribny IP. Noncoding RNA response to xenobiotic exposure: an indicator of toxicity and carcinogenicity. Expert Opin Drug Metab Toxicol 2014;10:1409-22
   PubMed Web of Science ®Google Scholar
• Vuppalanchi R, Liang T, Goswami CP, et al. Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis. PLoS One 2013;8:e74471
   PubMed Web of Science ®Google Scholar
• Lamba V, Ghodke Y, Guan W, Tracy TS. microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450. Biochem Biophys Res Commun 2014;445:404-11
   PubMed Web of Science ®Google Scholar
• Pogribny IP, Tryndyak VP, Boyko A, et al. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res 2007;619:30-7
   PubMed Web of Science ®Google Scholar
• Koufaris C, Wright J, Currie RA, Gooderham NJ. Hepatic microRNA profiles offer predictive and mechanistic insights after exposure to genotoxic and epigenetic hepatocarcinogens. Toxicol Sci 2012;128:532-43
   PubMed Web of Science ®Google Scholar
• Yang X, Greenhaw J, Shi Q, et al. Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity. Toxicol Sci 2012;125:335-44
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009;106:4402-7
   PubMed Web of Science ®Google Scholar
• Lee WM. Drug-induced acute liver failure. Clin Liver Dis 2013;17:575-86
   PubMed Web of Science ®Google Scholar
• Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012;56:1946-57
   PubMed Web of Science ®Google Scholar
• Starckx S, Batheja A, Verheyen GR, et al. Evaluation of miR-122 and other biomarkers in distinct acute liver injury in rats. Toxicol Pathol 2013;41:795-804
   PubMed Web of Science ®Google Scholar
• Starkey Lewis PJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011;54:1767-76
   PubMed Web of Science ®Google Scholar
• Antoine DJ, Dear JW, Starkey Lewis P, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013;58:777-87
   PubMed Web of Science ®Google Scholar
• Ward J, Kanchagar C, Veksler-Lublinsky I, et al. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc Natl Acad Sci USA 2014;111:12169-74
   PubMed Web of Science ®Google Scholar
• Krauskopf J, Caiment F, Claessen SM, et al. Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury. Toxicol Sci 2015;143(2):268-76
   PubMed Web of Science ®Google Scholar
• McClain RM. Phenobarbital mouse liver tumors: implications of hepatic tumor promotion for cancer risk assessment. Prog Clin Biol Res 1995;391:325-36
   PubMedGoogle Scholar
• Shizu R, Shindo S, Yoshida T, Numazawa S. MicroRNA-122 down-regulation is involved in phenobarbital-mediated activation of the constitutive androstane receptor. PLoS One 2012;7:e41291
   Google Scholar
• Koufaris C, Wright J, Osborne M, et al. Time and dose-dependent effects of phenobarbital on the rat liver miRNAome. Toxicology 2013;314:247-53
   PubMed Web of Science ®Google Scholar
• Lempiäinen H, Couttet P, Bolognani F, et al. Identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers for liver tumor promotion. Toxicol Sci 2013;131:375-86
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Tanaka S, Arai M, et al. Differences in microRNA changes of healthy rat liver between sevoflurane and propofol anesthesia. Anesthesiology 2012;117:1245-52
   PubMed Web of Science ®Google Scholar
• Van den Hof WF, Van Summeren A, Lommen A, et al. Integrative cross-omics analysis in primary mouse hepatocytes unravels mechanisms of cyclosporin A-induced hepatotoxicity. Toxicology 2014;324:18-26
   PubMed Web of Science ®Google Scholar
• Su Y-W, Chen X, Jiang Z-Z, et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats. PLoS One 2012;7:e37395
   PubMed Web of Science ®Google Scholar
• Tal TL, Tanguay RL. Non-coding RNAs – novel targets in neurotoxicity. Neurotoxicology 2012;33:530-44
   PubMed Web of Science ®Google Scholar
• Lei SY, Hache M, Loepke AW. Clinical research into anesthetic neurotoxicity: does anesthesia cause neurological abnormalities in humans? J Neurosurg Anesthesiol 2014;26:349-57
   PubMed Web of Science ®Google Scholar
• Twaroski DM, Yan Y, Olson JM, et al. Down-regulation of microRNA-21 is involved in the propofol-induced neurotoxicity observed in human stem cell-derived neurons. Anesthesiology 2014;121:786-800
   PubMed Web of Science ®Google Scholar
• Goto G, Hori Y, Ishikawa M, et al. Changes in the gene expression levels of microRNAs in the rat hippocampus by sevoflurane and propofol anesthesia. Mol Med Rep 2014;9:1715-22
   PubMed Web of Science ®Google Scholar
• Yang X, Yang Q, Wang X, et al. MicroRNA expression profile and functional analysis reveal that miR-206 is a critical novel gene for the expression of BDNF induced by ketamine. Neuromolecular Med 2014;16:594-605
   PubMed Web of Science ®Google Scholar
• Xu H, Zhang J, Zhou W, et al. The role of miR-124 in modulating hippocampal neurotoxicity induced by ketamine anesthesia. Int J Neurosci 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Jiang X-L, Du B-X, Chen J, et al. MicroRNA-34a negatively regulates anesthesia-induced hippocampal apoptosis and memory impairment through FGFR1. Int J Clin Exp Pathol 2014;7:6760-7
   PubMedGoogle Scholar
• Cao SE, Tian J, Chen S, et al. Role of miR-34c in ketamine-induced neurotoxicity in neonatal mice hippocampus. Cell Biol Int 2015;39:164-8
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhang Y. Desflurane accelerates neuronal cytotoxicity of Abeta by downregulating miR-214. Neurosci Lett 2013;554:28-33
   PubMed Web of Science ®Google Scholar
• Smirnova L, Block K, Sittka A, et al. MicroRNA profiling as tool for in vitro developmental neurotoxicity testing: the case of sodium valproate. PLoS One 2014;9:e98892
   Google Scholar
• Zhang Z, Convertini P, Shen M, et al. Valproic acid causes proteasomal degradation of DICER and influences miRNA expression. PLoS One 2013;8:e82895
   PubMed Web of Science ®Google Scholar
• Ogata K, Sumida K, Miyata K, et al. Circulating miR-9* and miR-384-5p as potential indicators for trimethyltin-induced neurotoxicity. Toxicol Pathol 2015;43:198-208
   PubMed Web of Science ®Google Scholar
• Muñoz-Culla M, Irizar H, Castillo-Triviño T, et al. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler 2014;20:1851-9
   PubMed Web of Science ®Google Scholar
• Kanki M, Moriguchi A, Sasaki D, et al. Identification of urinary miRNA biomarkers for detecting cisplatin-induced proximal tubular injury in rats. Toxicology 2014;324:158-68
   PubMed Web of Science ®Google Scholar
• Pavkovic M, Riefke B, Ellinger-Ziegelbauer H. Urinary microRNA profiling for identification of biomarkers after cisplatin-induced kidney injury. Toxicology 2014;324:147-57
   PubMed Web of Science ®Google Scholar
• Bhatt K, Zhou L, Mi Q-S, et al. MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. Mol Med 2010;16:409-16
   PubMed Web of Science ®Google Scholar
• Joo MS, Lee CG, Koo JH, Kim SG. miR-125b transcriptionally increased by Nrf2 inhibits AhR repressor, which protects kidney from cisplatin-induced injury. Cell Death Dis 2013;4:e899
   Google Scholar
• Pellegrini KL, Han T, Bijol V, et al. MicroRNA-155 deficient mice experience heightened kidney toxicity when dosed with cisplatin. Toxicol Sci 2014;141:484-92
   PubMed Web of Science ®Google Scholar
• Saikumar J, Hoffmann D, Kim T-M, et al. Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 2012;129:256-67
   PubMed Web of Science ®Google Scholar
• Jia P, Teng J, Zou J, et al. Intermittent exposure xenon protects against gentamicin-induced nephrotoxicity. PLoS One 2013;8:e64329
   PubMed Web of Science ®Google Scholar
• Damiano S, Ciarcia R, Montagnaro S, et al. Prevention of nephrotoxicity induced by cyclosporine-A: role of antioxidants. J Cell Biochem 2015;116:364-9
   PubMed Web of Science ®Google Scholar
• Chen J, Zmijewska A, Zhi D, Mannon RB. Cyclosporine-mediated allograft fibrosis is associated with micro-RNA-21 through AKT signaling. Transpl Int 2015;28:232-45
   PubMed Web of Science ®Google Scholar
• Pirmohamed M. Genetics and the potential for predictive tests in adverse drug reactions. Chem Immunol Allergy 2012;97:18-31
   Google Scholar
• Kaniwa N, Saito Y. Pharmacogenomics of severe cutaneous adverse reactions. Pharmacogenomics 2013;14:595-8
   PubMed Web of Science ®Google Scholar
• Lee H-M, Bguyen DT, Lu L-F. Progress and challenge of microRNA research in immunity. Front Genet 2014;5:178
   PubMed Web of Science ®Google Scholar
• Ichihara A, Wang Z, Jinnin M, et al. Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions. J Allergy Clin Immunol 2014;133:1065-74
   PubMed Web of Science ®Google Scholar
• Laterza OF, Lim L, Garrett-Engele PW, et al. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009;55:1977-83
   PubMed Web of Science ®Google Scholar
• Fan F, Sun A, Zhao H, et al. MicroRNA-34a promotes cardiomyocyte apoptosis post myocardial infarction through down-regulating aldehyde dehydrogenase 2. Curr Pharm Des 2013;19:4865-73
   PubMed Web of Science ®Google Scholar
• Tryndyak VP, Latendresse JR, Montgomery B, et al. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol 2012;262:52-9
   PubMed Web of Science ®Google Scholar
• Gatti DM, Lu L, Williams RW, et al. MicroRNA expression in the livers of inbred mice. Mutat Res 2011;714:126-33
   PubMed Web of Science ®Google Scholar
• Shan Z-X, Lin Q-X, Fu Y-H, et al. Upregulated expression of miR-1/miR-206 in rat model of myocardial infarction. Biochem Biophys Res Commun 2009;381:597-601
   PubMed Web of Science ®Google Scholar
• Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 2011;4:446-54
   PubMed Web of Science ®Google Scholar
• Harrill AH, Eaddy JS, Rose K, et al. Liver biomarker and in vitro assessment confirm the hepatic origin of aminotransferase elevations lacking histopathological correlate in beagle dogs treated with GABAA receptor antagonist NP260. Toxicol Appl Pharmacol 2014;277:131-7
   PubMed Web of Science ®Google Scholar
• Singhal R, Harrill AH, Menguy Vacheron F, et al. Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine. BMC Pharmacol Toxicol 2014;15:42
   PubMedGoogle Scholar
• Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem 2015;61:56-63
   PubMed Web of Science ®Google Scholar
• Zhao H, Shen J, Hu Q, et al. Effects of preanalytic variables on circulating microRNAs in whole blood. Cancer Epidemiol Biomarkers Prev 2014;23:2643-8
   PubMed Web of Science ®Google Scholar
• Daniels SI, Sillé FCM, Gouldbaum A, et al. Improving power to detect changes in blood miRNA expression by accounting for sources of variability in experimental designs. Cancer Epidemiol Biomarkers Prev 2014;23:2658-66
   PubMed Web of Science ®Google Scholar
• Miotto E, Saccenti E, Lupini L, et al. Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries. Cancers Epidemiol Biomarkers Prev 2014;23:2638-42
   PubMed Web of Science ®Google Scholar
• Aurora AB, Mahmoud AI, Luo X, et al. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca2+ overload and cell death. J Clin Invest 2012;122:1222-32
   PubMed Web of Science ®Google Scholar
• Narasimhan M, Riar AK, Rathinam ML, et al. Hydrogen peroxide responsive miR153 targets Nrf2/ARE cytoprotection in paraquat induced dopaminergic neurotoxicity. Toxicol Lett 2014;228:179-91
   PubMed Web of Science ®Google Scholar
• Lv G, Shao S, Dong H, et al. MicroRNA-214 protects cardiac myocytes against H2O2-induced injury. J Cell Biochem 2014;115:93-101
   PubMed Web of Science ®Google Scholar
• Tiao M-M, Wang F-S, Huang L-T, et al. MicroRNA-29a protects against acute liver injury in a mouse model of obstructive jaundice via inhibition of the extrinsic apoptosis pathway. Apoptosis 2014;19:30-41
   PubMed Web of Science ®Google Scholar